Ligand id: 8091

Name: reslizumab

Immunopharmacology Comments
Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Consequently survival and activity of eosinophils are reduced, lowering exacerbation rates and improving lung function in patients with severe eosinophilic asthma.
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Approved therapeutic as maintenance treatment for asthma in combination with other asthma medications.